ExScale
®
Biospecimen Solutions

Next Generation Nucleic Acid Extraction technology NGEx™

ExScale introduces automated, next generation technology for nucleic acid extraction from formalin-fixed, paraffin-embedded (FFPE) tissue sections using paramagnetic beads. The technology enables serial extraction of DNA and RNA from the same biospecimen where the isolated nucleic acids are of optimal quality for next generation sequencing and other downstream applications.

The company

ExScale Biospecimen Solutions is a Swedish company specializing in processes and know-how for nucleic acid extraction from human tissue specimens. The company was established in 2012 by researchers at Uppsala University and has since then developed and marketed their Next Generation Extraction technology, NGEx™, defined by innovative new methods and products for automated nucleic acid extractions.

Quality Assurance

ExScale has implemented a quality management system according to ISO13485 with CE marked products according to Directive 98/79/EC.

ExScale NGEx features

  • Fully automated extraction protocols (including tissue deparaffinisation)
  • Improved productivity and reduced turn-around time
  • Xylene-free deparaffinisation
  • Serial extraction of DNA and RNA from the same specimen
  • Enrichment of mRNA molecules
  • Minimal sample input
  • Reduced risk of cross contamination
  • Designed to be platform independent

Products

ExScale automated nucleic acid extraction solutions

ExScale’s nucleic acid isolation protocols use intuitive software, novel lysis buffer solutions and bead-based magnetic separation of DNA and RNA. ExScale protocols enable the extraction of DNA standalone or proprietary serial extraction of DNA and RNA from the same tissue specimen, and standalone HD-RNA™ enriching for mature RNA. ExScale's purification kits consist of plastic-ware, reagents packed into prefilled cartridges and a deparaffinisation reagent.

Purification kits

ExScale’s nucleic acid isolation protocols use intuitive software, novel lysis buffer solutions and magnetic separation of DNA and RNA-bound bead particles enabling DNA standalone or proprietary serial extraction of DNA and RNA from the same tissue, and standalone HD-RNA™ enriching for mature RNA. ExScale’s purification kits consist of plastic-ware, reagents packed into prefilled cartridges and a deparaffinisation reagent.

Software and Extraction Robots

ExScale’s purification technology utilizes a convenient bench-top Magtration® System 12GC Plus/UV robots (Precision System Science Co.,Ltd.) or Freedom EVO® workstation (Tecan) with the ability to simultaneously process up to 12 samples (Magtration® system) or 96 samples (Freedom EVO®).

Product Portfolio

ExScale NGEx kit
FFPE DNA FFPE HD-RNA FFPE serial DNA and total RNA Fresh-frozen serial DNA and total RNA
Automated extraction on 12-channel instrument ES-K110FP ES-K210HDFP ES-K110210FP ES-K110210F
Automated extraction on 96-channel instrument Not available Not available Not available ES-K110210FT
Kit inserts

FFPE DNA Purification Kit 48 reactions on Magtration® System

Cat # ES-K110FP

This kit is optimized for rapid and efficient purification of genomic DNA from FFPE tissue samples. The kit contains prefilled reagent cartridges and consumables for the fully automated extraction process. Purified DNA is of high yield and quality and is suitable for use in next generation sequencing, real time RT PCR, PCR and other downstream applications. This protocol is designed to minimize hands-on time and has a total turnaround time of 4 hours.

FFPE HD-RNA Purification Kit 48 reactions on Magtration® System

Cat # ES-K210HDFP

This kit contains a proprietary lysis buffer that allows a rapid and efficient enrichment of mature RNA from FFPE tissue samples. The protocol is optimized to minimize the exposure of samples to high temperature and long incubation times, thereby minimizing RNA degradation while maintaining high RNA yields. The kit contains prefilled reagents cartridges and consumables for the fully automated extraction process. Purified RNA is of optimal quality for next generation sequencing, real time RT PCR, PCR and other downstream application and is expected to improve clarity of results and reduce the cost of next generation sequencing. This protocol is designed to minimize hands-on time and has a total turnaround time of 2.5 hours.

FFPE DNA/RNA Purification Kit 48 reactions on Magtration® System

Cat # ES-K110210FP

This kit is optimized to allow the sequential purification of genomic DNA and total RNA from the same FFPE tissue sample. The kit contains prefilled reagents cartridges and consumables for the fully automated extraction process. DNA and total RNA are of suitable quality for next generation sequencing, real time RT PCR, PCR and other downstream application. This protocol is designed to minimize hands-on time and has a total turnaround time of 3.5 hours.

Fresh-frozen DNA/RNA Purification Kit 48 reactions on Magtration® System

Cat # ES-K110210F

This kit is optimized to allow the sequential purification of genomic DNA and total RNA from the same fresh-frozen tissue sample embedded in OCT or up to 1 x 106 cells. The kit contains prefilled reagents cartridges and consumables for the fully automated extraction process. DNA and total RNA are of suitable quality for next generation sequencing, real time RT PCR, PCR and other downstream application. This protocol is designed to minimize hands-on time and has a total turnaround time of 2 hours 15 mins.

Fresh-frozen DNA/RNA Purification Kit 96 reactions on Tecan Freedom EVO®

Cat # ES-K110210FT

This kit is optimized to allow the sequential purification of genomic DNA and total RNA from the same fresh-frozen tissue sample embedded in OCT. The kit contains reagents for the fully automated extraction process. DNA and total RNA are of suitable quality for next generation sequencing, real time RT PCR, PCR and other downstream application. This protocol is designed to minimize hands-on time and has a total turnaround time of 3 hours 20 mins.

Pipette tips

Orders

To place an order, please contact us.

Disclaimer: The ExScale Biospecimen products are currently not available for commercial distribution in the US.

Management

ExScale has an experienced management team and a board with a proven entrepreneurial track record. The team also has a global network of health care providers, and regulatory, design and production partners.

Sten Dahlborg

Sten Dahlborg

CEO

Sten Dahlborg has more than 20 years of international board and executive management experience in private start-up and public companies within the life science sector. In addition to his role as CEO of ExScale, Sten serves as a board director for a few companies within and outside the life science sector. Prior to joining ExScale, Sten served as the Senior Vice President and President for ArthroCare Corporation (NASDAQ: ARTC), and as the President for Medtronic Synectics Medical, Inc. (NYSE: MDT). Sten has a M. Sc. degree in Engineering Physics from Chalmers University of Technology.

Anna Pettersson

Anna Pettersson

VP, Regulatory Affairs and Quality Assurance

Anna Pettersson has several years of experience from management positions in companies in the life science industry; Synectics/Medtronic, ArthroCare Corp and ElectroCore LLC. She has gained experience from phases of start up through expansion – organic and acquisitions within infrastructure projects, marketing communication platforms, business practice and compliance as well as investor relations. She studied Information, Communication and Public Relations at the Institute of RMI Berghs and International Relations/Executive Assistant through the Stockholm University.

Lucy Mathot

Lucy Mathot

R&D Manager

Lucy Mathot is a postdoctoral researcher from the Department of Immunology, Genetics and Pathology at Uppsala University, Sweden. Lucy possesses broad experience in DNA and RNA extraction from tumors, whole blood and cultured cells, and extensive knowledge in different DNA and RNA-based diagnostic methods. Lucy co-founded ExScale™ in 2012.

Ammar Zaghlool

Ammar Zaghlool

Sales & Marketing Manager

Ammar Zaghlool is a postdoctoral researcher from the Science for Life Laboratory at Uppsala University, Sweden. Ammar has significant knowledge in applying, adapting and developing methods and technologies to enable comprehensive understanding of transcriptomes in health and disease, with extensive experience in genetic screening techniques. Ammar also has professional training in project management.

Karin Hartman

Karin Hartman

Production & Logistics Manager

With training in both business administration and biomedicine, Karin Hartman brings important competence in business and enterprise in the life science sector. She has broad experience in DNA and RNA extraction from tumors and cultured cells and possesses extensive knowledge in the field of molecular diagnostics.

Board of Directors

Tobias Sjöblom

Chairman

Tobias Sjöblom is Associate Professor at the Department of Immunology, Genetics and Pathology at Uppsala University, Sweden. With over 15 years of experience from cancer research, Tobias brings invaluable competence and knowledge about clinical demands and novel methods for screening, diagnostics and therapy. Tobias co-founded ExScale™ in 2012.

Allan Asp

Member

Allan Asp is investment manager at ALMI Invest AB, and possesses a long experience from marketing activities at life science companies like Pharmacia, Pyrosequencing and Alphahelix AB. He serves in the board of directors of Gradientech AB, Chromafora AB and WaveCraft i Uppsala AB.

Andy Browning

Member

Andy Browning is currently serving as a project manager at Uppsala University Innovation (UU Innovation) as well as an Interim Director of Business Creation at EIT Health. With a background of management positions from companies like Biovitrum, Arexis and Pharmacia & Upjohn, he brings valuable knowledge from the life science sector.

Careers

ExScale believe in a business culture where our employees can develop, both as individuals and in teams. We consider each person’s background and competence as strengths that can add creative solutions to the team as well as to the interactions with our customers, distributors and collaborators. Our employees are trained to work in many different environments with the same passion and goal in mind, which we believe creates knowledge and well-rounded individuals. If you are interested in being a part of our team, please forward your CV to info@exscalebio.com.

Collaboration

Do you share our vision and understanding of nucleic acid extractions and/or personalized medicine? ExScale welcomes your interest in collaboration with us by submitting a short description to info@exscalebio.com.

Exscale Bio group

For Investors

From nucleic acids to the new era of personalized cancer medicine

New understanding about the genetic composition of different cancer types has led to tailored cancer treatments using molecular diagnostic tests. Applicable to many aspects of patient management including diagnosis, prognosis and response to therapy; molecular diagnostic tests offer new hope for patients battling cancer, saving them from unnecessary toxicity while improving treatment outcome. One critical aspect in molecular diagnostics is related to the quality of the results, which depends largely upon the quality of genetic input material used, i.e. DNA and RNA. Currently, there is a demand for robust and automated solutions for extracting nucleic acids; DNA and RNA, without compromising on quality. To meet this growing need, ExScale have developed the Next Generation Extraction technology NGEx. NGEx is a novel technology which sets new standards for nucleic acid extraction and improves productivity for personalized medicine.

Market existence

ExScale intends to have a leading position in the markets in which we compete and to meet needs and preferences from our key stakeholders, including hospitals, research departments and industry. We are positioned to grow together with the major market trends where we believe that our serial DNA and RNA extraction technology, in combination with extraction of high definition (HD) RNA, will help drive the progression of personalized cancer medicine.

Resources

References

Efficient and scalable serial extraction of DNA and RNA from frozen tissue samples

Mathot L, Lindman M, Sjöblom T.Chem Commun 2011;47:547-9.

Automated serial extraction of DNA and RNA from biobanked tissue specimens

Mathot L, Wallin M, Sjöblom T. BMC Biotechnol, 13, 66.

Links